Although rtPA is the first-line treatment for ischemic stroke and is widely used in the clinical management of acute myocardial infarction (AMI), substantial doses are required for effective thrombolytic therapy, likely due to elevated plasma levels of PAI-1. Here, SERPINE1 is linked to ischemic stroke.